ZOMETA - ZOLEDRONIC ACID

Product Description

ZOMETA helps stop the debilitating effects of bone metastases

• The vicious cycle of bone destruction is ongoing and can have serious consequences
  for patients^5,6
• ZOMETA is proven to reduce and delay skeletal-related events (SREs) in multiple
  tumour types^2,3,7
  • — 40% reduction in relative risk of SREs in breast cancer
  • — 31% reduction in relative risk of SREs in lung cancer and other solid tumours
  • — 36% reduction in relative risk of SREs in prostate cancer
• Only dosing every 3 to 4 weeks is proven to protect patients from the devastating effects
  of bone metastases^2-4,7
• Dosing ZOMETA less frequently than at the approved schedule results in a significant loss
  of efficacy⁸
• ZOMETA has a well-established safety profile⁹